how should we deal with the barrage of new infertility treatments and innovative technologies?

How Should We Deal with the Barrage of New Infertility Treatments and Innovative Technologies?

Starting in 1970s as experimental procedures following numerous trial-and-error processes, assisted reproductive technologies (ART) have developed extensively through the past three decades. Following the successful birth of the first IVF baby, ART rapidly developed in both research and clinical practice during 1980s. Then after during1990s, IVF clinics, different ART methods and their success ...

How Do We Deal with Research Misconduct?

How should we deal with misattributed paternity? A survey of lay public attitudes

BACKGROUND Increasing use of genetic technologies in clinical and research settings increases the potential for misattributed paternity to be identified. Yet existing guidance from the President's Commission for the Study of Ethical Problems in Biomedical and Behavioral Research and the Institute of Medicine (among others) offers contradictory advice. Genetic health professionals are thus likel...

Multimodal Corpora : How Should Multimodal Corpora Deal with the Situation ?

The paper introduces the notion of multimodal cluster (MMC). MMC is a multicomponent spoken unit, which includes diads “meaning + gesture”, “meaning + phonetic phenomenon” (double MMC) or triad “meaning + gesture + phonetic phenomenon” (triple MMC). All components of the same MMC are synchronized in the speech, gestural and phonetic components conveying the same idea as the semantic component (...

“How should we treat older patients with Metastatic Colorectal Cancer, A Review”

Nearly 50 % of newly diagnosed colorectal cancer, affect people over 70 years of age. Inclusion of older patients in clinical trials has been extremely rare. As a result, there is debate on how to manage these patients because it is still unclear how to balance the therapeutic advantages and toxicities. For patients who do not have comorbid conditions, with performance status (P.S.) 0–1, treatm...

The diabetes dilemma: how do we deal with it?